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ABSTRACT 
 
The main objectives of the present research were to develop the new method for the simultaneous 
estimation and validation of Moxifloxacin HCl and Ketorolac Tromethamine in pure form and in 
pharmaceutical dosage form by RP-HPLC. The chromatogram of Moxifloxacin HCl and Ketorolac 
Tromethamine was developed through column (Inertsil ODS C18), UV detection at 304 nm at a flow rate of 
1.0 ml/min with Buffer (pH 4.0):Acetonitrile:Methanol (50:30:20) V/V as mobile phase. The method was 
validated by various validation parameters such as accuracy, precision, linearity, specificity as per the ICH 
guidelines. A linearity range of Moxifloxacin HCl and Ketorolac Tromethamine was found to be 60 to 140 
µg/ml and 48 to 112 µg/ml respectively. The retention time of Moxifloxacin HCl and Ketorolac 
Tromethamine was found to be 2.07 min and 4.06 min respectively. % RSD of retention time and peak areas 
obtained in system precision for Moxifloxacin HCl was 0.21 and 0.80 respectively and for Ketorolac 
Tromethamine were 0.90 and 1.06 respectively. The % recovery of standard Moxifloxacin HCl and Ketorolac 
Tromethamine was found to be 100.18 to 100.08% and 99.97 to 99.93% respectively. The % recovery of 
Moxifloxacin HCl and Ketorolac Tromethamine in dosage form was found to be 98.73 to 100.92% and 98.10 
to 100.77% respectively. This method was simple, accurate, precise and sensitive. Hence, the developed 
method was employed for the routine analysis of Tenofovir in pharmaceutical dosage form. 
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INTRODUCTION 
Moxifloxacin hydrochloride (MOX) is chemically 1-
Cyclopropyl-6-fluoro-1, 4-dihydro-8- methoxy-7-
[(4aS,7aS)-octahydro-6Hpyrrolo[3, 4- b]pyridin-6-
yl]-4-oxo-3 quinolinecarboxylic acid hydrochloride 
(Figure 1), which is a synthetic fourth generation 
broad-spectrum fluoroquinolone antibiotic. MOX acts 
by inhibiting type II topoisomerase, topoisomerase IV 
and DNA gyrase that are involved in the DNA 
replication and, metabolism[1]. 
 
Figure 1: Structure of Moxifloxacin HCl 
Ketorolac tromethamine (KET) is chemically (±)-5-
benzoyl-2,3- dihydro-1H-pyrrolizine-1-carboxylic 
acid, a compound with 2-amino-2-(hydroxymethyl)-
1,3- propanediol, which is a pyrrolizine carboxylic 
acid derivative (Figure 2). KET is nonsteroidal anti-
inflammatory drug used to treat short, moderate and 
severe pain and produce severe side effects, gastric 
bleeding. The combination of MOX and KET is broadly 
used for the treatment of postoperative inflammation 
and infection in the cataract surgery[1].  
 
Figure 2: Structure of Ketorolac Tromethamine 
Different methods such as estimation of MOX by UV 
spectrophotometry[1,2], estimation of MOX in 
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biological fluids by HPLC[3,4] and HPTLC[5] with other 
drugs were reported in the literature. 
Correspondingly, KET was determined by HPLC[6,7,8]. 
But, only some of the analytical methods were also 
reported for the simultaneous estimation of MOX and 
KET in a mixture by UV spectrophotometry[9], LC-
MS[10], stability indicating RP-HPLC[11], RP-HPLC[12,13] 
and HPTLC method[13]. A lot of literature review did 
not reveal that any simple and economical method for 
the simultaneous determination of MOX and KET in 
combined dosage forms by RP-HPLC. Hence, the 
attempts were made to develop and validate the 
simple, sensitive, precise, and isocratic RP-HPLC 
method for the simultaneous estimation of both 
drugs in pharmaceutical formulations. 
MATERIALS AND METHODS 
Materials 
Chemicals and reagents 
Moxifloxacin HCl & Keterolac bulk drugs and Eye 
drops (MOXICIP KT) were obtained from gift samples 
and Cipla pharmaceuticals. HPLC grade Methanol, 
Acetonitrile and Water were purchased from Merck 
Specialty Pvt Ltd. Potassium Dihydrogen Phosphate 
was procured from Rankem Chemicals. All the other 
chemicals and reagents used were of analytical grade 
and purchased from Finar chemicals limited and 
Fisher Scientific India Pvt Ltd.  
Instrumentation 
High performance liquid chromatographic system 
(Cyberlab) consisting of a pump, Hamilton injector, 
column (Zodiac ODS C18) equipped with UV-Visible 
detector and WS 100 workstation. Citizen, Digital 
Ultrasonic cleaner was used for sonication and Global 
DPH 500 pH meter was used for adjusting the pH of 
the buffer. Analytical Technologies UV-Visible 
Spectrophotometer was used for the detection and 
optimization of Wavelength. 
Preparation of 0.05 M potassium Dihydrogen 
Orthophosphate buffer pH 4.0 
3.4 gm of potassium dihydrogen phosphate was 
weighed and dissolved in 100 ml of water and volume 
was made up to 500 ml with water. Adjust the pH to 
4.0 ± 0.02 using Acetonitrile. The buffer was filtered 
through 0.45µm filters to remove all fine particles 
and gases. 
Method for selection of Wavelength 
Preparation of standard stock solution 
About 10 mg of Moxifloxacin HCl and 10 mg of 
Ketorolac Tromethamine were weighed into a 100 ml 
volumetric flask, to this 25 ml of methanol was added, 
sonicated for 10 minutes and the volume was made 
up to mark with the methanol. This solution was 
filtered through 0.45 μm filter.  
 
Preparation of working standard solution 
1 ml standard stock solution (100 µg/ml) was 
transferred into 10 ml volumetric flasks and the 
volume was made up to the mark with methanol (10 
µg/ml).  
Determination of detection Wavelength 
10 ml of working standard solution of Moxifloxacin 
HCl and Ketorolac Tromethamine (10 μg/ml) in 
methanol was scanned using UV-Visible 
spectrophotometer between wavelength ranges from 
190 to 400 nm against methanol as blank. 
Preparation of mobile phase 
Buffer (pH 4.0), Acetonitrile and Methanol were 
mixed in (50:30:20) V/V ration and the resulting 
solution was sonicated on a sonicator for 30 min, and 
then finally filtered through a 0.45µm membrane 
filter. 
Method development 
Preparation of Standard stock solution 
Weighed accurately about 60 mg of Moxifloxacin HCl 
and 48 mg of Ketorolac Tromethamine in 100 ml of 
the volumetric flask, dissolved with 25 mL of the 
mobile phase and sonicated for 10 minutes. The 
volume of the flask was made up to the mark with the 
mobile phase and filtered through a 0.45µm 
membrane filter.  
Preparation of working standard solution 
5 ml standard stock solution was pipetted out and 
transferred into 50 ml volumetric flask and the 
volume of the flask was made up to the mark with the 
mobile phase. 
Optimization of the method 
10 ml of working standard solution was injected with 
a flow rate of 1 ml/min at 304 nm. 
General procedure for construction of the 
calibration curve 
Aliquots of (0.6-1.4ml) the standard drug stock 
solutions (600 µg/ml of Moxifloxacin HCl and 480 
µg/ml of Ketorolac Tromethamine) were transferred 
into series of 10 ml volumetric flasks and the volume 
was made up to the mark with the mobile phase. This 
solution was sonicated, filtered and 10µl of this 
solution was injected into HPLC and analyzed. The 
calibration curve was constructed by plotting the 
peak area versus the respective drug concentrations 
of Moxifloxacin HCl (60-140µg/ml) and Ketorolac 
Tromethamine (48-112µg/ml). 
Estimation of Moxifloxacin HCl and Ketorolac 
Tromethamine (Assay) 
Preparation of Standard solution 
About 5 mg of Moxifloxacin HCl and 4 mg of Ketorolac 
Tromethamine were weighed into a 100 ml 
 R. Raghavi et al., (2020) Int. J. Res. Pharm. Sci & Tech., 2(1), 25-31 
Rubatosis Publications | International Journal of Research in Pharmaceutical Sciences and Technology 27  
volumetric flask, to this 25ml of the mobile phase was 
added, sonicated for 10 minutes and the volume was 
made up with the mobile phase. The resulting 
solution was filtered through a 0.45µm membrane 
filter. 
Preparation of Sample solution 
5ml of 25 mg of Moxifloxacin HCl and 4ml of 20 mg of 
Ketorolac tromethamine transferred 25ml 
volumetric flask, 10 ml of the mobile was added, and 
then sonicated for 5 minutes. The volume of the flask 
was made up to 25 ml with mobile phase.  
Preparation of working sample solution 
Transferred 5.0 ml of stock solution into 50 ml of 
volumetric flask and made up to volume with the 
mobile phase. 
HPLC method validation 
Precision 
Preparation of standard Moxifloxacin HCl 
solution: 5mg of Moxifloxacin HCl was taken in a 100 
ml volumetric flask, dissolved in 25 ml of the mobile 
phase and sonicated for 10 minutes. The volume of 
the flask was made up to 100ml with the mobile 
phase and the resulting solution was filtered through 
a 0.45µm membrane filter. From this, 1ml of the 
solution was pipetted out and diluted to 10 ml with 
the mobile phase. 
Preparation of standard Ketorolac 
Tromethamine solution: 4mg of Ketorolac 
Tromethamine was taken in a 100 ml volumetric 
flask, dissolved in 25 ml of the mobile phase and 
sonicated for 10 minutes. The volume of the flask was 
make up to 100ml with mobile phase and the 
resulting solution was filtered through a 0.45µm 
membrane filter. From this, 1ml of the solution was 
pipetted out and diluted to 10 ml with the mobile 
phase. 
RESULTS AND DISCUSSIONS 
Selection of Wavelength 
The absorption curve shows characteristic 
absorption maxima at 297 nm for Moxifloxacin HCl 
(Figure 3), at 320 nm for Ketorolac Tromethamine 
(Figure 3) and 304 nm the same absorbance for both 
the drugs. Thus 304 nm was selected as the detector 
wavelength for the HPLC chromatographic method.
 
Figure 3: UV chromatogram of Moxifloxacin HCl and 
Ketorolac Tromethamine 
Optimization method 
The Moxifloxacin HCl peak was observed at 2.077 min 
with peak area 6172.055, and theoretical plates of 
4263. The Ketorolac Tromethamine peak was 
observed at 4.067 min with peak area 4716.017 and 
theoretical plates of 5357 (Table 1). The peaks of 
Moxifloxacin HCl and Ketorolac Tromethamine were 
eluted properly (Figure 4). Hence this method was 
considered for further development.  
Table 1: Results of Chromatogram of Moxifloxacin HCl 
and Ketorolac Tromethamine by using Phosphate 
buffer:Acetonitrile:Methanol (50:30:20) pH:4.0 
S.N
O 
Name RT Height Area TP 
1 
Moxifloxacin 
HCl 
2.07
7 
615.19
0 
6172.05
5 
426
3 
2 
Ketorolac 
Tromethamin
e 
4.06
7 
378.25
3 
4716.01
7 
535
7 
 
Figure 4: Chromatogram of Moxifloxacin HCl and 
Ketorolac Tromethamine by using Phosphate 
buffer:Acetonitrile:Methanol (50:30:20) pH:4.0 
Linearity and range 
A graph was plotted for Moxifloxacin HCl and 
Ketorolac Tromethamine against the concentrations 
of the solutions and the peak areas (Table 2 & Table 
3). The correlation coefficient R2 was determined and 
was found to be 0.9979 for Moxifloxacin HCl (Figure 
5) and 0.9977 for Ketorolac Tromethamine (Figure 
6). 
Table 2: Linearity data of Moxifloxacin HCl and 
Ketorolac Tromethamine 
S. No. 
Moxifloxacin HCl Ketorolac Tromethamine 
µg/mL Area µg/mL Area 
1 60 4127.217 48 3132.14 
2 80 5252.73 64 4001.261 
3 100 6259.872 80 4809.099 
4 120 7432.037 96 5733.133 
5 140 8740.281 112 6772.281 
Estimation of Moxifloxacin HCl and Ketorolac 
Tromethamine (Assay) 
The peak area for Moxifloxacin HCl and Ketorolac 
Tromethamine were 6266.333 and 4775.51 (Table 
4). The % purity of Moxifloxacin HCl and Ketorolac 
Tromethamine were 99.49 and 100.83 (Table 3).  
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Table 3: Statistical data of the regression equations for determination of Moxifloxacin HCl and Ketorolac 
Tromethamine 
Parameter Moxifloxacin HCl Ketorolac Tromethamine 
Linearity range (µg/mL) 60-140 48-112 
Regression equation (y) 659.71+57.02x 383.51+56.32x 
Intercept (b) 659.71 383.51 
Slope (a) 57.02 56.32 
Correlation coefficient (r) 0.9979 0.9977 
 
 
Figure 5: Graph for Linearity data of Moxifloxacin 
HCl 
 
Figure 6: Graph for Linearity data of Ketorolac Tro-
methamine 
Table 4: Overview Results of Assay 
Specifications Moxifloxacin HCl Ketorolac Tromethamine 
Standard peak area 
6257.131 4775.456 
6240.905 4749.875 
6261.565 4810.414 
6265.919 4733.082 
6274.786 4800.199 
Average 6260.061 4773.805 
Sample peak area 
6287.440 4737.976 
6274.464 4808.420 
6254.069 4781.101 
6274.786 4800.199 
6240.905 4749.875 
6266.333 4775.51 
Amount of standard (in mg) 4.97 4.03 
Amount of sample (in mg) 25.2 20.2 
% purity of standard 98.6 99.8 
% purity of sample 99.49 100.83 
Table 5: Precision results of Moxifloxacin HCl and Ketorolac Tromethamine 
S. No. 
Moxifloxacin HCl Ketorolac Tromethamine 
Retention time Peak area Retention time Peak area 
1 2.077 6137.949 4.067 4716.017 
2 2.077 6204.208 4.107 4712.087 
3 2.070 6145.971 4.117 4705.468 
4 2.073 6187.949 4.130 4724.778 
5 2.083 6276.876 4.180 4838.002 
6 2.077 6190.210 4.107 4760.061 
Average 2.0762 6190.527 4.118 4742.736 
Standard Deviation 0.0044 49.799 0.037 50.479 
% RSD 0.21 0.80 0.90 1.06 
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Hence % purity of both drugs was found to be within 
the limits (98-102 %). 
System precision 
The system precision was determined by analyzing 
the standard preparation of Moxifloxacin HCl and 
Ketorolac Tromethamine for six times. The 
chromatograms were recorded and the results were 
summarized in Table 5. % RSD of retention time and 
peak areas obtained for Moxifloxacin HCl was 0.21 
and 0.80 respectively and for Ketorolac 
Tromethamine were 0.90 and 1.06 respectively. 
Limit of detection (LOD) and limit of quantitation 
(LOQ) 
The LOD for this method was found to be 1.83µg/ml 
for Moxifloxacin HCl and 1.48µg/ml for Ketorolac 
Tromethamine respectively. The LOQ for this method 
was found to be 5.55µg/ml for Moxifloxacin Hcl and 
4.49µg/ml for Ketorolac Tromethamine respectively.  
Table 6: Accuracy results of standard Moxifloxacin HCl and Ketorolac Tromethamine 
Concentration 
(µg/ml) 
Peak area 
Amount 
(µg) 
Average amount 
(µg) 
Standard 
deviation 
% Recovery % RSD 
Moxifloxacin HCl 
80 
5252.73 80.09 
80.14 0.046 100.18 0.057 5258.69 80.15 
5241.56 80.18 
100 
6259.872 100.05 
100.09 0.045 100.09 0.045 6260.865 100.09 
6259.853 100.14 
120 
7432.037 120.15 
120.10 0.045 100.08 0.037 7432.031 120.10 
7433.027 120.06 
Ketorolac Tromethamine 
64 
4001.261 63.91 
63.98 0.076 99.97 0.119 4001.256 64.06 
4001.260 63.96 
80 
4809.099 80.07 
79.94 0.113 99.92 0.141 4809.120 79.91 
4809.156 79.85 
96 
5733.133 96.02 
95.93 0.095 99.93 0.099 5733.245 95.83 
5733.210 95.94 
 
Table 7: Accuracy results of standard Moxifloxacin HCl and Ketorolac Tromethamine by standard addition 
method 
Concentration 
(µg/ml) 
Peak area Amount (µg) 
Average 
Amount (µg) 
Standard deviation % Recovery % RSD 
Moxifloxacin HCl 
80+20 
6792.409 98.73 
98.73 0.057 98.73 0.058 6403.692 98.76 
6259.324 98.84 
100+20 
7659.385 121.45 
121.53 0.078 101.27 0.064 7730.537 121.56 
7432.037 121.60 
120+20 
8689.774 141.26 
141.29 0.031 100.92 0.022 8821.788 141.32 
8740.235 141.28 
Ketorolac Tromethamine 
64+16 
5157.593 78.41 
78.48 0.015 98.1 0.019 4832.731 78.43 
4729.099 78.44 
80+16 
5829.489 96.75 
96.98 0.21 101.02 0.217 5926.363 97.15 
5733.133 97.04 
96+16 
6785.489 113.91 
113.99 0.28 101.78 0.246 6864.216 114.30 
6772.281 113.76 
 
 R. Raghavi et al., (2020) Int. J. Res. Pharm. Sci & Tech., 2(1), 25-31 
30  Rubatosis Publications | International Journal of Research in Pharmaceutical Sciences and Technology 
 
Validation of the methods 
Procedure for the standard: Samples of the 
standard were prepared and tested at three levels 
such as 80, 100, 120 µg/ml for Moxifloxacin HCl and 
64, 80, 96 µg/ml Ketorolac Tromethamine by the 
proposed method. Samples of samples were prepared 
and tested at three levels such as 80, 96, 112 µg/ml 
by standard addition method, in which variable 
amounts of a previously analyzed portion of a 
standard drug were added to the sample (Table 6 and 
Table 7). The average percent recovery of standard 
and samples were found to be 93.96–100.7% and 
respectively, indicates the good accuracy of the 
method. 
CONCLUSION 
The proposed RP-HPLC (Reverse Phase High 
performance Liquid Chromatography) method has 
been evaluated for accuracy, precision and linearity. 
The method was found to be precise, accurate and 
linear over the linear concentration range. The 
analytical method validation of Moxifloxacin HCl and 
Ketorolac Tromethamine by RP-HPLC was found to 
be satisfactory and could be used for the routine 
pharmaceutical analysis of Moxifloxacin HCl and 
Ketorolac Tromethamine. The method was validated 
as per ICH guidelines. Therefore, this HPLC method 
can be used as routine analysis of these drugs in bulk, 
pharmaceutical formulations and also for stability 
studies.  
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